Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 2, 2008, Pages 203-210

  Ikawa, K ^a   Morikawa, N ^a   Ikeda, K ^a   Miki, M ^a   Nishimura, S ^a   Kobayashi, M ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Biapenem; Paediatrics; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BIAPENEM;

ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PEDIATRICS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CREATININE; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; THIENAMYCINS;

EID: 40349103380     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00908.x     Document Type: Article

References (24)

1. Perry CM, Ibbotson T (2002) Biapenem. Drugs, 62, 2221 2234.
2. Nakashima M, Uematsu T, Ueno K et al. (1993) Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 31, 70 76.
3. Nasu M, Gotoh Y, Yamasaki T et al. (1994) Basic and clinical studies on biapenem, a new carbapenem antibiotic, in respiratory tract infections. Japanese Journal of Chemotherapy, 42, 418 425.
4. Kozawa O, Uematsu T, Matsuno H et al. (1998) Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrobial Agents and Chemotherapy, 42, 1433 1436.
5. Fujii R, Fujita K, Yoshikawa M et al. (1994) Pharmacokinetic and clinical studies with L-627 (biapenem) in the pediatric field. Japanese Journal of Antibiotics, 47, 530 552.
6. Tajima T, Niimi R, Kobayashi M et al. (1994) Pharmacokinetic, bacteriological and clinical studies on biapenem (L-627) in children. Japanese Journal of Antibiotics, 47, 896 902.
7. Toynaga Y, Ishihara T, Tezuka T et al. (1994) Pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field. Japanese Journal of Antibiotics, 47, 1691 1705.
8. Drusano GL (2003) Prevention of resistance: a goal for dose selection for antimicrobial agents. Clinical Infectious Diseases, 36, S42 S50.
9. Takata T, Aizawa K, Shimizu A, Sakakibara S, Watabe H, Totsuka K (2004) Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. Journal of Infection and Chemotherapy, 10, 76 85.
10. Burmaster DE, Anderson PD (1994) Principles of good practice for the use Monte Carlo techniques in human health and ecological risk assessments. Risk Analysis, 14, 477 481.
11. Drusano GL, Preston SL, Hardalo C et al. (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrobial Agents and Chemotherapy, 45, 13 22.
12. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. Journal of Antimicrobial Chemotherapy, 55, 601 607.
13. Meguro H, Fujii R, Terashima I et al. (1994) Clinical evaluation of a new carbapenem antibiotic, biapenem (L-627), in the pediatric field. Japanese Journal of Antibiotics, 47, 903 913.
14. Iwai N, Nakamura H, Taneda Y (1994) Pharmacokinetic, bacteriological and clinical evaluation of biapenem (L-627) in the pediatric field. Japanese Journal of Antibiotics, 47, 1706 1722.
15. Motohiro T, Handa S, Yamada S et al. (1994) Bacteriological, pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field. Japanese Journal of Antibiotics, 47, 1728 1752.
16. Ikeda K, Ikawa K, Ikeda A, Nishikawa Y, Morikawa N (2006) A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 844, 148 152.
17. Yanagi K, Sunakawa M, Kagami K, Matsumoto S, Kitamura M (1994) Assay of biapenem in human body fluids. Japanese Journal of Chemotherapy, 42, 229 242.
18. Coulthard MG (1994) Surface area is best estimated from weight alone: pocket calculators and nomograms are unnecessary. Archives of Disease in Childhood, 71, 281.
19. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31 41.
20. Yamaguchi K, Murakami M, Takahashi A et al. (2005) Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Japanese Journal of Antibiotics, 58, 655 689.
21. Koeppe P, Hoffler D, Fitzen B (1997) Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittel- Forschung, 47, 1250 1256.
22. Aoki N, Usuda Y, Koda Y et al. (1994) Clinical pharmacology and efficacy of biapenem. Japanese Journal of Chemotherapy, 42, 350 364.
23. Shiba K, Maezawa H, Yoshida M, Sakai O, Saito A (1994) Basic and clinical studies of biapenem. Japanese Journal of Chemotherapy, 42, 322 329.
24. Tajima N, Ishizuka H, Naganuma H (2006) Population pharmacokinetic analysis of panipenem/ betamipron in patients with various degrees of renal function. Chemotherapy, 52, 245 253.